Sherry Rohekar, BSc., MD, FRCPC, MSc - Targeting the IL-17 Pathway in PsA and axSpA: Precision Strategies for Patient-Centered Care

Please visit answersincme.com/NHE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.

There are no comments yet.

Please log in to write the first comment.